Top

World Journal of Surgery

Published in:

01-11-2010

Histological and Immediate Postoperative Outcome after Preoperative Cetuximab: Case-Matched Control Study

Authors: Patrick Pessaux, Ettore Marzano, Selenia Casnedi, Philippe Bachellier, Daniel Jaeck, Marie-Pierre Chenard

Published in: World Journal of Surgery | Issue 11/2010

Abstract

Background

The aim of this study was to analyze the effects of preoperative cetuximab (cetu) on nontumorous liver parenchyma and the clinical and biological outcomes after liver resection for colorectal liver metastases (CLM).

Methods

Between January 2005 and June 2009, 26 patients who received preoperative cetu were matched to a control group of 26 patients who did not receive cetu. They were matched on the basis of age, gender, body mass index, extent of hepatectomy, and type and number of cycles of neoadjuvant chemotherapy.

Results

Liver function tests, postoperative outcome, and histopathology of the resected liver were compared. There was no mortality. Postoperative morbidity and perioperative bleeding rates were similar in both groups. Serum aspartate aminotransferase and serum alanine aminotransferase were higher on postoperative day 5 in the control group (p = 0.02 and p = 0.04, respectively). In the cetu group, the postoperative peaks of γ-glutamyl transpeptidase and alkaline phosphatase were statistically higher than in the control group. Interestingly, pathological review of the nontumorous liver parenchyma revealed no significant difference between patients who received cetu and those treated without cetu with respect to prevalence of steatosis, steatohepatitis, sinusoidal obstructive syndrome, and fibrosis.

Conclusions

The addition of cetu to the neoadjuvant chemotherapy regimens does not appear to increase the morbidity rate after hepatectomy for CLM, and also in cases of major hepatectomy. The pathological examination did not show additional injury to the nontumorous liver parenchyma.

Simmonds PC, Primrose JN, Colquitt JL et al (2006) Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 94:982–999CrossRefPubMed

Jaeck D, Pessaux P (2008) Bilobar colorectal liver metastases: treatment options. Surg Oncol Clin N Am 17:553–568CrossRefPubMed

Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMed

Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466CrossRefPubMed

Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after pre-operative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:845–853

Karoui M, Penna C, Amin-Hashem M et al (2006) Influence of chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243:1–7CrossRefPubMed

Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefPubMed

Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pre-treatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853CrossRefPubMed

Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072CrossRefPubMed

10.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342CrossRefPubMed

11.

Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed

12.

Adam R, Aloia T, Lévi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593–4602CrossRefPubMed

13.

D’Angelica M, Kornprat P, Gonen M et al (2006) Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol 14:759–765CrossRefPubMed

14.

Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96–106CrossRefPubMed

15.

Ribero D, Wang H, Donadon M et al (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110:2761–2767CrossRefPubMed

16.

Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515–520PubMed

17.

Chun YS, Vauthey JN (2007) Extending the frontiers of respectability in advanced colorectal cancer. Eur J Surg Oncol 33(Suppl 2):S52-S58

18.

Giraudo G, Greget M, Oussoultzoglou E et al (2008) Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. Surgery 143:476–482CrossRefPubMed

19.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213CrossRefPubMed

20.

Balzan S, Belghiti J, Farges O et al (2005) The “50–50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242:824–829CrossRefPubMed

21.

Ozier Y, Pessione F, Samain E et al (2003) French Study Group on blood transfusion in liver transplantation. Institutional variability in transfusion practice for liver transplantation. Anesth Analg 97:671–679CrossRefPubMed

22.

Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 41:1313–1321CrossRefPubMed

23.

Brunt EM (2000) Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31:241–246CrossRefPubMed

24.

Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMed

25.

Panaro F, Casnedi S, Zeca I et al (2008) Conséquences cliniques, biologiques et histologiques du cetuximab et du bevacizumab après hépatectomie pour métastases d’origine colo-rectale: étude cas-témoin. J Chir 145:10S26

26.

Farges O, Belghiti J, Kianmanesh R et al (2003) Portal vein embolization before right hepatectomy: Prospective clinical trial. Ann Surg 237:208–217CrossRefPubMed

27.

Suc B, Panis Y, Belghiti J et al (1992) Natural history of hepatectomy. Br J Surg 79:39–42CrossRefPubMed

28.

Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803–812CrossRefPubMed

29.

Buckley AF, Burgart LJ, Kakar S (2006) Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carinoma. Hum Pathol 37:410–414CrossRefPubMed

30.

Reinehr R, Becker S, Eberle A et al (2005) Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis. J Biol Chem 280:27179–27194CrossRefPubMed

Title: Histological and Immediate Postoperative Outcome after Preoperative Cetuximab: Case-Matched Control Study
Authors: Patrick Pessaux
Ettore Marzano
Selenia Casnedi
Philippe Bachellier
Daniel Jaeck
Marie-Pierre Chenard
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 11/2010
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-010-0731-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Histological and Immediate Postoperative Outcome after Preoperative Cetuximab: Case-Matched Control Study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2010

Must Breast Care Delivery Models from Resource-Rich Environments be Applied to Resource-Limited Environments?

Long-Term Results of Esophagogastric Devascularization and Splenectomy Associated with Endoscopic Treatment in Schistosomal Portal Hypertension

Foley Catheter Enterostomy for Postoperative Bowel Perforation: An Effective Source Control

Vascular Reconstruction During Pancreatoduodenectomy for Ductal Adenocarcinoma of the Pancreas Improves Resectability but does not Achieve Cure

Balancing Resource Constraints against Quality of Care

Prognostic Value of Body Mass Index on Short-Term and Long-Term Outcome after Resection of Esophageal Cancer